HRP20170185T1 - Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba - Google Patents
Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba Download PDFInfo
- Publication number
- HRP20170185T1 HRP20170185T1 HRP20170185TT HRP20170185T HRP20170185T1 HR P20170185 T1 HRP20170185 T1 HR P20170185T1 HR P20170185T T HRP20170185T T HR P20170185TT HR P20170185 T HRP20170185 T HR P20170185T HR P20170185 T1 HRP20170185 T1 HR P20170185T1
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- compound
- solvates
- salts
- image
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (13)
1. Spoj s formulom (I)
[image]
naznačen time da
R1 predstavlja vodik ili fluor,
L1 predstavlja etan-1,2-diil ili 1,4-fenilen,
i
A predstavlja skupinu s formulom
[image]
u kojoj
* označava odgovarajuću točku vezanja na ostatak molekule,
L3 predstavlja vezu, -O-, -CH2-, -CH2-CH2- ili -CH=CH-,
i
R3C predstavlja supstituent odabran iz skupine koja sadrži fluor, klor, brom, cijano, (C1-C4)-alkil, difluormetil, trifluormetil, (C1-C4)-alkoksi, difluormetoksi i trifluormetoksi,
i R3D predstavlja supstituent odabran iz skupine koja sadrži vodik, fluor, klor, brom, cijano, (C1-C4)-alkil, difluormetil, trifluormetil, (C1-C4)-alkoksi, difluormetoksi i trifluormetoksi,
i soli, solvati i solvati njihovih soli.
2. Spoj s formulom (I) prema zahtjevu 1, naznačen time da
R1 predstavlja vodik ili fluor,
L1 predstavlja etan-1,2-diil ili 1,4-fenilen,
i
A predstavlja skupinu s formulom
[image]
u kojoj
* označava odgovarajuću točku vezanja na ostatak molekule,
L3 predstavlja vezu, -CH2-CH2- ili -CH=CH-,
R3C predstavlja fluor, klor, metil ili trifluormetil,
i
R3D predstavlja vodik, fluor, klor, cijano, metil, trifluormetil, metoksi ili trifluormetoksi,
i soli, solvati i solvati njihovih soli.
3. Spoj s formulom (I) prema zahtjevu 1 ili 2, naznačen time da
R1 predstavlja vodik ili fluor,
L1 predstavlja etan-1,2-diil ili 1,4-fenilen,
i
A predstavlja skupinu s formulom
[image]
u kojoj
* označava odgovarajuću točku vezanja na ostatak molekule,
L3 predstavlja vezu, -CH2-CH2- ili -CH=CH-,
R3C predstavlja fluor, klor, metil ili trifluormetil,
i
R3D predstavlja vodik, fluor, klor, cijano, metil, trifluormetil ili trifluormetoksi,
i soli, solvati i solvati njihovih soli.
4. Spoj s formulom (I) prema zahtjevu 1, 2 ili 3, naznačen time da
R1 predstavlja vodik ili fluor,
L1 predstavlja etan-1,2-diil ili 1,4-fenilen,
i
A predstavlja skupinu s formulom
[image]
u kojoj
* označava odgovarajuću točku vezanja na ostatak molekule,
L3 predstavlja vezu ili -CH2-CH2-,
R3C predstavlja klor,
i
R3D predstavlja vodik, fluor ili trifluormetil,
i soli, solvati i solvati njihovih soli.
5. 5-{[2-(4-karboksifenil)etil][2-(2-{[3-klor-4'-(trifluormetil)bifenil-4-il]metoksi}fenil)etil]amino}-5,6,7,8-tetrahidrokinolin-2-karboksilna kiselina prema formuli u nastavku
[image]
i soli, solvati i solvati njihovih soli.
6. 5-{(4-karboksibutil)[2-(2-{[3-klor-4'-(trifluormetil)bifenil-4-il]metoksi}fenil)etil]amino}-5,6,7,8-tetrahidrokinolin-2-karboksilna kiselina prema formuli u nastavku
[image]
i soli, solvati i solvati njihovih soli.
7. Postupak za pripremanje spoja s formulom (I) kako je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time da ili
[A] spoj s formulom (II)
[image]
u kojoj R1 i L1 imaju značenja dodijeljena u bilo kojem od zahtjeva 1 do 6 i
T1 i T2 su identični ili različiti i predstavljaju (C1-C4)-alkil,
reagira u prisutnosti baze sa spojem s formulom (III)
[image]
u kojoj A ima značenja dodijeljena u bilo kojem od zahtjeva 1 do 6 i
X1 predstavlja odlazeću skupinu kao što je, na primjer, klor, brom, jod, mesilat, triflat ili tosilat,
ili
[B] spoj s formulom (IV)
[image]
u kojoj R1 i A imaju značenja dodijeljena u bilo kojem od zahtjeva 1 do 6 i
T2 predstavlja (C1-C4)-alkil,
reagira u prisutnosti baze sa spojem s formulom (V)
[image]
u kojoj L1 ima značenja dodijeljena u bilo kojem od zahtjeva 1 do 6,
T1 predstavlja (C1-C4)-alkil,
i
X2 predstavlja odlazeću skupinu kao što je, na primjer, klor, brom, jod, mesilat, triflat ili tosilat,
i odgovarajući nastali spoj s formulom (VI)
[image]
u kojoj R1, A, L1, T1 i T2 imaju gore navedena značenja,
se zatim prevodi hidrolizom skupina estera -C(O)OT1 i -C(O)OT2 u odgovarajuću dikarboksilnu kiselinu s formulom (I)
i na ovaj način dobiveni spojevi s formulom (I) se proizvoljno rastavljaju na njihove enantiomere i/ili dijastereomere i/ili proizvoljno prevode s odgovarajućim (i) otapalima i/ili (ii) bazama ili kiselinama u njihove solvate, soli i/ili solvate soli.
8. Spoj kako je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time da je za liječenje i/ili prevenciju bolesti.
9. Spoj kako je definirano u bilo kojem od zahtjeva 1 do 6, naznačen time da je za uporabu u postupku za liječenje i/ili prevenciju primarnih i sekundarnih oblika plućne hipertenzije, zatajenja srca, angine pektoris, hipertenzije, tromboembolijskih poremećaja, ishemija, vaskularnih poremećaja, oštećenja mikrocirkulacije, insuficijencije bubrega, fibroznih poremećaja i arterioskleroze.
10. Uporaba spoja kako je definirano u bilo kojem od zahtjeva 1 do 6, naznačena time da je za dobivanje lijeka za liječenje i/ili prevenciju primarnih i sekundarnih oblika plućne hipertenzije, zatajenja srca, angine pektoris, hipertenzije, tromboembolijskih poremećaja, ishemija, vaskularnih poremećaja, oštećenja mikrocirkulacije, insuficijencije bubrega, fibroznih poremećaja i arterioskleroze.
11. Lijek, naznačen time da sadrži spoj kako je definirano u bilo kojem od zahtjeva 1 do 6 u kombinaciji s jednom ili više inertnih netoksičnih farmaceutski prihvatljivih pomoćnih tvari.
12. Lijek, naznačen time da sadrži spoj kako je definirano u bilo kojem od zahtjeva 1 do 6 u kombinaciji s jednim ili više daljnjih aktivnih spojeva koji su odabrani iz skupine koju čine organski nitrati, donori NO, inhibitori PDE 5, analozi prostaciklina, agonisti IP receptora, antagonisti receptora endotelina, stimulatori gvanilat ciklaze, inhibitori tirozin kinaze, anti-opstruktivna sredstva, protuupalna i/ili imunosupresivna sredstva, antitrombotici, sredstva za snižavanje krvnog tlaka i sredstva koja mijenjaju metabolizam masti.
13. Lijek prema zahtjevu 11 ili 12, naznačen time da je za liječenje i/ili prevenciju primarnih i sekundarnih oblika plućne hipertenzije, zatajenja srca, angine pektoris, hipertenzije, tromboembolijskih poremećaja, ishemija, vaskularnih poremećaja, oštećenja mikrocirkulacije, insuficijencije bubrega, fibroznih poremećaja i arterioskleroze.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177284 | 2012-07-20 | ||
| EP13167967 | 2013-05-16 | ||
| PCT/EP2013/065017 WO2014012934A1 (de) | 2012-07-20 | 2013-07-16 | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
| EP13744464.2A EP2875003B1 (de) | 2012-07-20 | 2013-07-16 | Neue 5-aminotetrahydrochinolin-2-carbonsäuren und ihre verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170185T1 true HRP20170185T1 (hr) | 2017-03-24 |
Family
ID=48914233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170185TT HRP20170185T1 (hr) | 2012-07-20 | 2013-07-16 | Nove 5-aminotetrahidrokinolin-2-karboksilne kiseline i njihova uporaba |
Country Status (40)
| Country | Link |
|---|---|
| US (3) | US8981104B2 (hr) |
| EP (1) | EP2875003B1 (hr) |
| JP (1) | JP6251259B2 (hr) |
| KR (1) | KR102137517B1 (hr) |
| CN (1) | CN104822661B (hr) |
| AR (1) | AR091838A1 (hr) |
| AU (1) | AU2013292046C1 (hr) |
| BR (1) | BR112015001211B1 (hr) |
| CA (1) | CA2879369C (hr) |
| CL (1) | CL2015000120A1 (hr) |
| CO (1) | CO7240369A2 (hr) |
| CR (1) | CR20150020A (hr) |
| CY (1) | CY1118588T1 (hr) |
| DK (1) | DK2875003T3 (hr) |
| DO (1) | DOP2015000012A (hr) |
| EA (1) | EA028918B9 (hr) |
| EC (1) | ECSP15001882A (hr) |
| ES (1) | ES2616036T3 (hr) |
| GT (1) | GT201500011A (hr) |
| HR (1) | HRP20170185T1 (hr) |
| HU (1) | HUE030540T2 (hr) |
| IL (1) | IL236616B (hr) |
| JO (1) | JO3343B1 (hr) |
| LT (1) | LT2875003T (hr) |
| ME (1) | ME02603B (hr) |
| MX (1) | MX360863B (hr) |
| MY (1) | MY172994A (hr) |
| NZ (1) | NZ702977A (hr) |
| PE (1) | PE20150350A1 (hr) |
| PH (1) | PH12015500106B1 (hr) |
| PL (1) | PL2875003T3 (hr) |
| PT (1) | PT2875003T (hr) |
| RS (1) | RS55651B1 (hr) |
| SG (2) | SG10201700454PA (hr) |
| SI (1) | SI2875003T1 (hr) |
| TN (1) | TN2015000026A1 (hr) |
| TW (1) | TWI598338B (hr) |
| UY (1) | UY34918A (hr) |
| WO (1) | WO2014012934A1 (hr) |
| ZA (1) | ZA201409394B (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| KR20140144696A (ko) | 2012-04-16 | 2014-12-19 | 도아 에이요 가부시키가이샤 | ２환성 화합물 |
| HK1211282A1 (en) | 2012-07-20 | 2016-05-20 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane-and aminotetralincarboxylic acids and use thereof |
| DK2875003T3 (en) * | 2012-07-20 | 2017-02-20 | Bayer Pharma AG | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THE USE OF IT |
| FR3000065A1 (fr) * | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
| CN107250113B (zh) | 2014-10-07 | 2019-03-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调节蛋白的调节剂的共晶 |
| US20180169095A1 (en) | 2015-05-06 | 2018-06-21 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
| CN113750102A (zh) | 2015-07-23 | 2021-12-07 | 拜耳制药股份公司 | 可溶性鸟苷酸环化酶的刺激剂和/或活化剂及其用途 |
| AU2017300558B2 (en) * | 2016-07-22 | 2021-02-25 | Toa Eiyo Ltd. | Therapeutic agent for glaucoma |
| WO2018069148A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc aktivatoren und mineralocorticoid-rezeptor-antagonisten |
| WO2018153899A1 (de) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit stimulatoren und/oder aktivatoren der löslichen guanylatcyclase (sgc) |
| MX2020004190A (es) | 2017-10-24 | 2020-08-03 | Bayer Ag | Amidas de imidazopiridina sustituidas y su uso. |
| WO2019081456A1 (en) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT |
| EP3498298A1 (en) | 2017-12-15 | 2019-06-19 | Bayer AG | The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi) |
| CN108218770A (zh) * | 2018-02-28 | 2018-06-29 | 南京波普生物医药研发有限公司 | 2-氯-7,8-二氢-6h-喹啉-5-酮的制备方法 |
| CN112055584A (zh) | 2018-04-30 | 2020-12-08 | 拜耳公司 | sGC活化剂和sGC刺激剂用于治疗认知障碍的用途 |
| JP2021523201A (ja) | 2018-05-15 | 2021-09-02 | バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 神経線維感作に関連する疾患を治療するための１，３−チアゾール−２−イル置換ベンズアミド |
| US11508483B2 (en) | 2018-05-30 | 2022-11-22 | Adverio Pharma Gmbh | Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group |
| US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
| US20220128561A1 (en) | 2019-01-17 | 2022-04-28 | Bayer Aktiengesellschaft | Methods to determine whether a subject is suitable of being treated with an agonist of soluble gyanylyl cyclase (sgc) |
| WO2020164008A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
| WO2020216669A1 (de) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Phenylsubstituierte imidazopyridinamide und ihre verwendung |
| CN114585637B (zh) | 2019-05-07 | 2025-04-15 | 拜耳公司 | Masp抑制化合物及其用途 |
| EP3822265A1 (en) | 2019-11-15 | 2021-05-19 | Bayer AG | Substituted hydantoinamides as adamts7 antagonists |
| EP3822268A1 (en) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Substituted hydantoinamides as adamts7 antagonists |
| JP7835690B2 (ja) * | 2020-05-20 | 2026-03-25 | バイエル・アクチエンゲゼルシヤフト | ブチル－（５ｓ）－５－（｛２－［４－（ブトキシカルボニル）フェニル］エチル｝［２－（２－｛［３－クロロ－４′－（トリフルオロメチル）［ビフェニル］－４－イル］メトキシ｝フェニル）エチル］アミノ）－５，６，７，８－テトラヒドロキノリン－２－カルボキシレートの製造方法 |
| KR20240144178A (ko) | 2021-12-29 | 2024-10-02 | 바이엘 악티엔게젤샤프트 | 심폐 장애의 치료 |
| EP4457215A1 (en) | 2021-12-29 | 2024-11-06 | Bayer Aktiengesellschaft | Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] 2-(2-{ 3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound |
| CA3244896A1 (en) | 2021-12-29 | 2023-07-06 | Bayer Aktiengesellschaft | Pharmaceutical dry powder inhalation formulation |
| CA3258617A1 (en) | 2022-06-09 | 2023-12-14 | Bayer Aktiengesellschaft | SOLUBLE GUANYLATE CYCLASE ACTIVATORS FOR USE IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION IN WOMEN |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8004002L (sv) | 1980-05-29 | 1981-11-30 | Arvidsson Folke Lars Erik | Terapeutiskt anvendbara tetralinderivat |
| IL65501A (en) | 1981-05-08 | 1986-04-29 | Astra Laekemedel Ab | 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| DE3719924A1 (de) | 1986-12-22 | 1988-06-30 | Bayer Ag | 8-substituierte 2-aminotetraline |
| CA2051399C (en) | 1989-05-31 | 2003-12-30 | Chiu-Hong Lin | Therapeutically useful 2-aminotetralin derivatives |
| FR2659853A1 (fr) | 1990-03-22 | 1991-09-27 | Midy Spa | Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale. |
| EP0738149B1 (en) | 1994-01-10 | 2006-11-29 | Teva Pharmaceutical Industries, Ltd. | 1-aminoindan derivatives and compositions thereof |
| WO1999062505A2 (en) | 1998-06-01 | 1999-12-09 | Ortho-Mcneil Pharmaceutical, Inc. | Method for treating neurodegenerative disorders |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9827467D0 (en) | 1998-12-15 | 1999-02-10 | Zeneca Ltd | Chemical compounds |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10109859A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige Aminodicarbonsäurederivate |
| DE10109861A1 (de) | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate |
| DE10109858A1 (de) * | 2001-03-01 | 2002-09-05 | Bayer Ag | Neuartige halogensubstituierte Aminodicarbonsäurederivate |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US20050032873A1 (en) | 2003-07-30 | 2005-02-10 | Wyeth | 3-Amino chroman and 2-amino tetralin derivatives |
| GB0318094D0 (en) * | 2003-08-01 | 2003-09-03 | Pfizer Ltd | Novel combination |
| WO2006104826A2 (en) | 2005-03-30 | 2006-10-05 | Merck & Co., Inc. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| DE102005047946A1 (de) * | 2005-10-06 | 2007-05-03 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von akuten und chronischen Lungenkrankheiten |
| DE102005050377A1 (de) | 2005-10-21 | 2007-04-26 | Bayer Healthcare Ag | Heterocyclische Verbindungen und ihre Verwendung |
| DE102006031175A1 (de) * | 2006-07-06 | 2008-01-10 | Bayer Healthcare Ag | Wässrige Arzneimittelformulierung von 4-[((4-Carboxybutyl)-(2[(4-phenethyl-benzyl)oxy]-phenethyl)amino)methyl]benzoesäur |
| US20090048295A1 (en) | 2007-08-13 | 2009-02-19 | Joseph Kent Barbay | Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof |
| CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| ES2610882T3 (es) * | 2008-08-19 | 2017-05-03 | Janssen Pharmaceutica, N.V. | Antagonistas del receptor al mentol frío |
| DE102010020553A1 (de) | 2010-05-14 | 2011-11-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2585055A1 (de) | 2010-06-25 | 2013-05-01 | Bayer Intellectual Property GmbH | Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen |
| CA2804470A1 (en) | 2010-07-09 | 2012-01-12 | Bayer Intellectual Property Gmbh | Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| JP5715713B2 (ja) | 2011-03-10 | 2015-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性グアニル酸シクラーゼ活性化因子 |
| KR20140144696A (ko) * | 2012-04-16 | 2014-12-19 | 도아 에이요 가부시키가이샤 | ２환성 화합물 |
| HK1211282A1 (en) | 2012-07-20 | 2016-05-20 | Bayer Pharma Aktiengesellschaft | Substituted aminoindane-and aminotetralincarboxylic acids and use thereof |
| DK2875003T3 (en) * | 2012-07-20 | 2017-02-20 | Bayer Pharma AG | NEW 5-AMINOTETRAHYDROQUINOLINE-2-CARBOXYLIC ACIDS AND THE USE OF IT |
-
2013
- 2013-07-16 DK DK13744464.2T patent/DK2875003T3/en active
- 2013-07-16 SG SG10201700454PA patent/SG10201700454PA/en unknown
- 2013-07-16 MY MYPI2015000125A patent/MY172994A/en unknown
- 2013-07-16 LT LTEP13744464.2T patent/LT2875003T/lt unknown
- 2013-07-16 ME MEP-2017-30A patent/ME02603B/me unknown
- 2013-07-16 WO PCT/EP2013/065017 patent/WO2014012934A1/de not_active Ceased
- 2013-07-16 ES ES13744464.2T patent/ES2616036T3/es active Active
- 2013-07-16 NZ NZ702977A patent/NZ702977A/en unknown
- 2013-07-16 SI SI201330514A patent/SI2875003T1/sl unknown
- 2013-07-16 SG SG11201408421TA patent/SG11201408421TA/en unknown
- 2013-07-16 EP EP13744464.2A patent/EP2875003B1/de active Active
- 2013-07-16 CA CA2879369A patent/CA2879369C/en active Active
- 2013-07-16 PL PL13744464T patent/PL2875003T3/pl unknown
- 2013-07-16 AU AU2013292046A patent/AU2013292046C1/en active Active
- 2013-07-16 HR HRP20170185TT patent/HRP20170185T1/hr unknown
- 2013-07-16 KR KR1020157001058A patent/KR102137517B1/ko active Active
- 2013-07-16 HU HUE13744464A patent/HUE030540T2/en unknown
- 2013-07-16 CN CN201380048579.2A patent/CN104822661B/zh active Active
- 2013-07-16 EA EA201590251A patent/EA028918B9/ru not_active IP Right Cessation
- 2013-07-16 JP JP2015522074A patent/JP6251259B2/ja active Active
- 2013-07-16 MX MX2015000739A patent/MX360863B/es active IP Right Grant
- 2013-07-16 RS RS20170110A patent/RS55651B1/sr unknown
- 2013-07-16 PE PE2015000049A patent/PE20150350A1/es active IP Right Grant
- 2013-07-16 PT PT137444642T patent/PT2875003T/pt unknown
- 2013-07-16 BR BR112015001211-6A patent/BR112015001211B1/pt active IP Right Grant
- 2013-07-18 JO JOP/2013/0216A patent/JO3343B1/ar active
- 2013-07-18 AR ARP130102566A patent/AR091838A1/es active IP Right Grant
- 2013-07-18 US US13/945,675 patent/US8981104B2/en active Active
- 2013-07-19 UY UY0001034918A patent/UY34918A/es active IP Right Grant
- 2013-07-19 TW TW102125865A patent/TWI598338B/zh active
-
2014
- 2014-12-19 ZA ZA2014/09394A patent/ZA201409394B/en unknown
-
2015
- 2015-01-11 IL IL236616A patent/IL236616B/en active IP Right Grant
- 2015-01-14 PH PH12015500106A patent/PH12015500106B1/en unknown
- 2015-01-15 CO CO15007422A patent/CO7240369A2/es unknown
- 2015-01-16 CL CL2015000120A patent/CL2015000120A1/es unknown
- 2015-01-16 DO DO2015000012A patent/DOP2015000012A/es unknown
- 2015-01-19 TN TNP2015000026A patent/TN2015000026A1/fr unknown
- 2015-01-19 EC ECIEPI20151882A patent/ECSP15001882A/es unknown
- 2015-01-20 CR CR20150020A patent/CR20150020A/es unknown
- 2015-01-20 GT GT201500011A patent/GT201500011A/es unknown
- 2015-01-29 US US14/609,122 patent/US9688636B2/en active Active
-
2017
- 2017-02-03 CY CY20171100161T patent/CY1118588T1/el unknown
- 2017-05-19 US US15/600,132 patent/US10053428B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02603B (me) | Nove 5 - aminotetrahidrohinolin-2-karbonske kiseline i njihova upotreba | |
| RU2012121577A (ru) | Замещенные 3-фенилпропионовые кислоты и их применение | |
| HRP20150702T1 (hr) | Supstituirani 4-aril-1,4-dihidro-1,6-naftiridinamidi i njihova uporaba | |
| IL298983B2 (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| HRP20171950T1 (hr) | Pirimidinoni kao inhibitori faktora xia | |
| JPWO2008149965A1 (ja) | ピリドン化合物 | |
| HRP20150341T1 (hr) | Heterocikliäśki supstituirani spojevi arila kao inhibitori hif | |
| WO2015154673A1 (en) | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases | |
| JP2012526769A5 (hr) | ||
| SI2956464T1 (en) | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors (neutral endopeptidases) | |
| JP6428763B2 (ja) | アミド化合物 | |
| HUT67666A (en) | Biphenylil methyl pyrimidine derivatives having angiotensine ii antagonistic activity and pharmaceutical compositions containing them | |
| US20040002493A1 (en) | Benzoic acid derivatives and pharmaceutical agents comprising the same as active ingredient | |
| HU199430B (en) | Herbicides comprising 1h-imidazole derivatives as active ingredient and process for producing the compounds | |
| JP2020514372A (ja) | ブチルフタリド−テルミサルタン混成物、その調製方法及びその応用 | |
| RU2005137155A (ru) | Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина | |
| JP2025509134A (ja) | ラリネパグプロドラッグおよびその使用 | |
| JP2021042207A (ja) | トロンボキサン受容体アンタゴニスト | |
| PT594019E (pt) | Bifenilos trissubstituidos como antagonistas da angiotensina ii | |
| SG188245A1 (en) | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | |
| DK165950B (da) | Fremgangsmaade til fremstilling af herbicide 2-(4,4-disubstitueret-5-oxo-2-imidazolin-2-yl)benzoesyrer, -nicotinsyrer og -quinolin-3-carboxylsyrer, estere og salte deraf | |
| RU2015105603A (ru) | Антагонисты минералокортикоидных рецепторов | |
| WO2004000813A1 (ja) | フェノキシピリジン誘導体又はその塩 | |
| RU2007132438A (ru) | Циклопропил-(2,3-диметилбензил)амид 7-{4-[2-(2,6-дихлор-4-метилфенокси)этокси]фенил}-3,9-диазабицикло[3.3.1]нон-6-ен-6-карбоновой кислоты в качестве ингибиторов ренина для лечения артериальной гипертензии | |
| WO2019029295A1 (zh) | 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用 |